Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalff, V.
Right arrow Articles by Ball, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalff, V.
Right arrow Articles by Ball, D. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 1 (January), 2001: 111-118
© 2001 American Society for Clinical Oncology

Clinical Impact of 18F Fluorodeoxyglucose Positron Emission Tomography in Patients With Non–Small-Cell Lung Cancer: A Prospective Study

By Victor Kalff, Rodney J. Hicks, Michael P. MacManus, David S. Binns, Allan F. McKenzie, Robert E. Ware, Annette Hogg, David L. Ball

From the Department of Nuclear Medicine, Alfred Hospital, Prahran, and Departments of Diagnostic Imaging and Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

Address reprint to Rod Hicks, MD, FRACP, Director of Diagnostic Imaging, PET Center, Peter MacCallum Cancer Institute, 12 Cathedral Place, East Melbourne VIC 3002, Australia; email rhicks@ petermac.unimelb.edu.au.

PURPOSE: To prospectively study the impact of 18F fluorodeoxyglucose (FDG) positron emission tomography (PET) on clinical management of patients with non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: One hundred five consecutive patients with NSCLC undergoing 18F FDG PET were analyzed. Before PET, referring physicians recorded scan indication, conventional clinical stage, and proposed treatment plan. PET scan results were reported in conjunction with available clinical and imaging data, including results of computed tomography (CT). Subsequent management and appropriateness of PET-induced changes were assessed by follow-up for at least 6 months or until the patient’s death.

RESULTS: Indications for PET were primary staging (n = 59), restaging (n = 34), and suspected malignancy subsequently proven to be NSCLC (n = 12). In 27 (26%) of 105 of cases, PET results led to a change from curative to palliative therapy by upstaging disease extent. Validity of the PET result was established in all but one case. PET appropriately downstaged 10 of 16 patients initially planned for palliative therapy, allowing either potentially curative treatment (four patients) or no treatment (six patients). PET influenced the radiation delivery in 22 (65%) of 34 patients who subsequently received radical radiotherapy. Twelve patients considered probably inoperable on conventional imaging studies were downstaged by PET and underwent potentially curative surgery. PET missed only one primary tumor (5-mm scar carcinoma). CT and PET understaged three of 20 surgical patients (two with N1 lesions < 5 mm and one with unrecognized atrial involvement), and PET missed one small intrapulmonary metastasis apparent on CT. No pathological N2 disease was missed on PET.

CONCLUSION: FDG PET scanning changed or influenced management decisions in 70 patients (67%) with NSCLC. Patients were frequently spared unnecessary treatment, and management was more appropriately targeted.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
R. Bordoni
Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer
Oncologist, September 1, 2008; 13(9): 945 - 953.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, B. A. Siegel, D. Liu, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and R. E. Coleman
Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
J. Clin. Oncol., May 1, 2008; 26(13): 2155 - 2161.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
J. F. Bruzzi, R. Komaki, G. L. Walsh, M. T. Truong, G. W. Gladish, R. F. Munden, and J. J. Erasmus
Imaging of Non-Small Cell Lung Cancer of the Superior Sulcus: Part 2: Initial Staging and Assessment of Resectability and Therapeutic Response
RadioGraphics, March 1, 2008; 28(2): 561 - 572.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta
18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review
J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. E. Hillner, D. Liu, R. E. Coleman, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and B. A. Siegel
The National Oncologic PET Registry (NOPR): Design and Analysis Plan
J. Nucl. Med., November 1, 2007; 48(11): 1901 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. L. Port, P. C. Lee, R. J. Korst, Y. Liss, D. Meherally, P. Christos, M. Mazumdar, and N. K. Altorki
Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma
Ann. Thorac. Surg., August 1, 2007; 84(2): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K G Tournoy, S Maddens, R Gosselin, G Van Maele, J P van Meerbeeck, and A Kelles
Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study
Thorax, August 1, 2007; 62(8): 696 - 701.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L.-F. Wang, H. Chu, Y.-M. Chen, and R.-P. Perng
Adenocarcinoma of the Lung Presenting as a Mycetoma With an Air Crescent Sign
Chest, April 1, 2007; 131(4): 1239 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. J. Biehl, F.-M. Kong, F. Dehdashti, J.-Y. Jin, S. Mutic, I. El Naqa, B. A. Siegel, and J. D. Bradley
18F-FDG PET Definition of Gross Tumor Volume for Radiotherapy of Non-Small Cell Lung Cancer: Is a Single Standardized Uptake Value Threshold Approach Appropriate?
J. Nucl. Med., November 1, 2006; 47(11): 1808 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tsurutani, M. S. Ballas, and P. A. Dennis
Overestimating the Influence of the 1999 WHO Classification of Lung Tumors on Survival in Bronchioloalveloar Carcinoma
J. Clin. Oncol., April 20, 2006; 24(12): 1963 - 1963.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Hishida, K. Nagai, J. Yoshida, M. Nishimura, G.-i. Ishii, M. Iwasaki, and Y. Nishiwaki
Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?
J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 838 - 842.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard
Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer
J. Nucl. Med., April 1, 2006; 47(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]

Home page
 RadiologyHome page
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart
Imaging of the Patient with Non-Small Cell Lung Cancer
Radiology, December 1, 2005; 237(3): 803 - 818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8362 - 8370.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Sachs and T. V. Bilfinger
The Impact of Positron Emission Tomography on Clinical Decision Making in a University-Based Multidisciplinary Lung Cancer Practice
Chest, August 1, 2005; 128(2): 698 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, R. Tunuguntla, and M. Fratkin
Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States Center
J. Clin. Oncol., October 15, 2004; 22(20): 4147 - 4156.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. J. Wirth, A. T. Skarin, and D. J. Sugarbaker
Reply
Clin. Cancer Res., April 15, 2004; 10(8): 2904 - 2904.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Halter, A. K. Buck, H. Schirrmeister, I. Wurziger, F. Liewald, G. Glatting, B. Neumaier, L. Sunder-Plassmann, S. N. Reske, and M. Hetzel
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1093 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. F. Kelly, T. Tran, A. Holmstrom, J. Murar, and R. J. Segurola Jr
Accuracy and Cost-Effectiveness of [18F]-2-Fluoro-Deoxy-D-Glucose-Positron Emission Tomography Scan in Potentially Resectable Non-small Cell Lung Cancer
Chest, April 1, 2004; 125(4): 1413 - 1423.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. L. Port, M. S. Kent, R. J. Korst, R. Keresztes, M. A. Levin, and N. K. Altorki
Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer
Ann. Thorac. Surg., January 1, 2004; 77(1): 254 - 259.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens
Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis
Ann Intern Med, December 2, 2003; 139(11): 879 - 892.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. H. Kernstine
Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy?
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1700 - 1703.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. V. Gonzalez-Stawinski, A. Lemaire, F. Merchant, E. O'Halloran, R. E. Coleman, D. H. Harpole, and T. A. D'Amico
A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1900 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
U. Pastorino, G. Veronesi, C. Landoni, M. Leon, M. Picchio, P. G. Solli, F. Leo, L. Spaggiari, G. Pelosi, M. Bellomi, et al.
Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1906 - 1910.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel
Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG
J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. Berger, M. K. Gould, and P. G. Barnett
The Cost of Positron Emission Tomography in Six United States Veterans Affairs Hospitals and Two Academic Medical Centers
Am. J. Roentgenol., August 1, 2003; 181(2): 359 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen
A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Lardinois, W. Weder, T. F. Hany, E. M. Kamel, S. Korom, B. Seifert, G. K. von Schulthess, and H. C. Steinert
Staging of Non-Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography
N. Engl. J. Med., June 19, 2003; 348(25): 2500 - 2507.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. V. Dizendorf, B. G. Baumert, G. K. von Schulthess, U. M. Lutolf, and H. C. Steinert
Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients for Radiation Therapy
J. Nucl. Med., January 1, 2003; 44(1): 24 - 29.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G J Herder, H van Tinteren, E F Comans, O S Hoekstra, G J Teule, P E Postmus, U Joshi, and E F Smit
Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer
Thorax, January 1, 2003; 58(1): 47 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. A. D'Amico, T. Z. Wong, D. H. Harpole, S. D. Brown, and R. E. Coleman
Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies
Ann. Thorac. Surg., July 1, 2002; 74(1): 160 - 163.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. M. Kamel, G. W. Goerres, C. Burger, G. K. von Schulthess, and H. C. Steinert
Recurrent Laryngeal Nerve Palsy in Patients with Lung Cancer: Detection with PET-CT Image Fusion—Report of Six Cases
Radiology, July 1, 2002; 224(1): 153 - 156.
[Abstract] [Full Text]

Home page
 JNMHome page
M. A. Seltzer, C. S. Yap, D. H. Silverman, J. Meta, C. Schiepers, M. E. Phelps, S. S. Gambhir, J. Rao, P. E. Valk, and J. Czernin
The Impact of PET on the Management of Lung Cancer: The Referring Physician's Perspective
J. Nucl. Med., June 1, 2002; 43(6): 752 - 756.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, H. Schirrmeister, M. Hetzel, M. von der Heide, G. Halter, G. Glatting, T. Mattfeldt, F. Liewald, S. N. Reske, and B. Neumaier
3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography for Noninvasive Assessment of Proliferation in Pulmonary Nodules
Cancer Res., June 1, 2002; 62(12): 3331 - 3334.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A G Pitman, R J Hicks, D S Binns, R E Ware, V Kalff, A F McKenzie, D L Ball, and M P MacManus
Performance of sodium iodide based 18F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses
Br. J. Radiol., February 1, 2002; 75(890): 114 - 121.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Hicks, V. Kalff, M. P. MacManus, R. E. Ware, A. Hogg, A. F. McKenzie, J. P. Matthews, and D. L. Ball
18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in Staging Newly Diagnosed Non-Small Cell Lung Cancer
J. Nucl. Med., November 1, 2001; 42(11): 1596 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Hicks, V. Kalff, M. P. MacManus, R. E. Ware, A. F. McKenzie, J. P. Matthews, and D. L. Ball
The Utility of 18F-FDG PET for Suspected Recurrent Non-Small Cell Lung Cancer After Potentially Curative Therapy: Impact on Management and Prognostic Stratification
J. Nucl. Med., November 1, 2001; 42(11): 1605 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Laking and P Price
18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer
Thorax, September 1, 2001; 56(90002): ii38 - 44.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online